Soligenix to Present Promising HyBryte™ Treatment Results at US Cutaneous Lymphoma Consortium Workshop 2026

Soligenix Announces Presentation of HyBryte™ Treatment Results

Soligenix, Inc. (Nasdaq: SNGX), a biopharmaceutical company focused on developing therapies for rare diseases, will showcase the positive findings from its recent studies on HyBryte™ at the 2026 US Cutaneous Lymphoma Consortium (USCLC) Workshop. This event, which occurs just before the American Academy of Dermatology (AAD) Annual Meeting, is scheduled for March 26, 2026, in Princeton, New Jersey.

Highlighting the Research

At the USCLC workshop, Dr. Ellen Kim, a leading dermatology expert and Principal Investigator for the Phase 3 FLASH trial, will present the significant results of HyBryte™. This novel treatment has shown promising outcomes for patients suffering from cutaneous T-cell lymphoma (CTCL), a rare form of skin cancer characterized by malignant T-cell lymphocytes. The data to be shared encompasses an investigator-initiated study that underscores HyBryte™'s effectiveness as a long-term treatment option.

Alongside Dr. Kim's oral presentation, a poster will be presented by Dr. Christopher Pullion, which compares the efficacy of HyBryte™ against Valchlor® (mechlorethamine), highlighting its relative advantages in the treatment landscape.

The Science Behind HyBryte™

HyBryte™ (SGX301) employs a unique photodynamic therapy mechanism that utilizes a synthetic substance, hypericin, activated by safe visible light. When applied to skin lesions, this approach specifically targets malignant T-cells while minimizing damage to surrounding healthy tissue. The treatment's efficacy has been well-documented in clinical trials, with results showing statistical significance in lesion reduction compared to placebo treatments.

The first Phase 3 FLASH trial, consisting of 169 patients, demonstrated that about 16% of those treated with HyBryte™ experienced a reduction of at least 50% in their lesions after eight weeks, a significant improvement over the 4% observed in the placebo group. The continued analysis through additional treatment cycles indicated even more promising response rates, establishing HyBryte™ as a potential front-line therapy for CTCL, particularly in patients who have not previously responded to other treatments.

Future Directions and Confirmatory Study

Encouraged by the findings and the requirement of a second Phase 3 trial to secure marketing approval from the FDA and EMA, Soligenix has initiated the FLASH2 study. This confirmatory trial aims to replicate the double-blind, placebo-controlled methodology of the first FLASH study while extending the treatment duration to 18 weeks to evaluate HyBryte's™ long-term efficacy.

The safety profile of HyBryte™ continues to be a critical consideration for both patients and regulatory bodies. The treatment is associated with minimal systemic absorption and non-mutagenic characteristics, making it a safer alternative to traditional therapies that often come with severe side effects, including an increased risk of skin cancers.

Conclusion

The upcoming presentation at the USCLC Workshop represents an important milestone for Soligenix, demonstrating its commitment to advancing innovative treatments for CTCL. As it continues its clinical endeavors with HyBryte™, the company is poised to provide better therapeutic options for patients battling this challenging disease. With the collaborative aspects of the workshop fostering dialogue among specialists, the potential for HyBryte™ to become a cornerstone treatment for CTCL grows stronger. More information about Soligenix and HyBryte™ can be found on their official website, where ongoing updates about their research and future developments will be provided.

For further inquiries or to learn more about the event, visit the USCLC meeting's official page.